000806.SZライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (5 7月 2023 @ 15:57):

Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China...

Stats
本日の出来高	33.86M
平均出来高	8.81M
時価総額	461.96M
EPS	CNY-0.0663 ( 2023-03-31 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-1.313
ATR14	CNY0.0550 (12.79%)

ボリューム相関

長: -0.25 (neutral)

短: -0.56 (weak negative)

Signal:(15.824) Neutral

Galaxy Biomedical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Galaxy Biomedical 相関 - 通貨/商品

-0.86
( strong negative )

-0.36
( neutral )

0.00
( neutral )

-0.60
( weak negative )

0.86
( strong )

Galaxy Biomedical 財務諸表

Annual	2022
収益:	CNY1.53B
総利益:	CNY542.64M (35.51 %)
EPS:	CNY-0.310

FY	2022
収益:	CNY1.53B
総利益:	CNY542.64M (35.51 %)
EPS:	CNY-0.310

FY	2021
収益:	CNY1.14B
総利益:	CNY425.76M (37.21 %)
EPS:	CNY-0.875

FY	2020
収益:	CNY1.11B
総利益:	CNY385.19M (34.83 %)
EPS:	CNY0.0530

Financial Reports:

No articles found.

Galaxy Biomedical

Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. The company produces and sells various transformer products, such as power, rectifier, and special transformers for use in metal smelting, electrochemistry, and power grid companies; and manufactures and sells electronic components, including displacement sensors, brake resistance boxes, radio frequency components, resistors, potentiometers, and others for use in aviation, aerospace, weapons, ships, AI intelligence, new energy, rail transit, communications, smart grids, instrumentation and other fields. It also offers animal products, and monoclonal antibody and targeted drugs, as well as drugs for the treatment of cancer and other diseases; laboratory equipment; and CRO, CAR-T technology and stem cell technology research and development, malignant cancer immune cell technology, and genetic testing services. The company also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.